<p>纽约花园城，2025 年 12 月 30 日（GLOBE NEWSWIRE）-- Beyond Air, Inc.（纳斯达克：XAIR）（“Beyond Air” 或 “公司”）是一家商业阶段的医疗设备和生物制药公司，专注于利用一氧化氮（NO）的力量改善患者的生活，今天宣布任命 Dan Moorhead 为首席财务官，任职将于 2026 年 1 月 5 日生效。公司的控制人 Duke Dewrell 在 2025 年 11 月临时担任首席财务官的职责，将于该日期恢复其之前的角色。</p>
<p>“很高兴欢迎 Dan 加入 Beyond Air 团队，” Beyond Air 的董事长兼首席执行官 Steve Lisi 表示。“他在引导公司经历显著增长和发展高效的财务组织方面拥有强大的业绩记录，这些组织能够支持商业规模。我期待利用他的经验，继续推进我们的战略，建立一家市场领先的公司。”</p>
<p>“我很荣幸在公司发展如此关键的时刻加入 Beyond Air 团队。随着市场对 LungFit PH 的认知不断提升，团队为第二代 LungFit PH 的 FDA 批准和随后的商业发布做准备，我期待与领导团队紧密合作，以确保强有力的财务管理，并支持我们商业战略的成功执行，” Moorhead 先生表示。</p>
<p>Moorhead 先生在公共和私人公司拥有超过 20 年的财务领导经验。从 2017 年 6 月到 2025 年 8 月，他担任 Zynex, Inc.的首席财务官，这是一家上市的商业阶段医疗设备公司，在那里他实施了严格的预算和预测框架，并支持公司的多年商业扩展。在加入 Zynex 之前，Moorhead 先生在 Evolving Systems, Inc.（被 PartnerOne, Inc.收购）工作了 10 年，担任首席财务官，之前曾担任财务与行政副总裁和公司控制人。Moorhead 先生是注册会计师，并拥有北科罗拉多大学的会计学学士学位。</p>
<p>与他的任命相关，公司根据纳斯达克证券市场上市规则 5635(c)(4) 向 Moorhead 先生授予了一项诱导股票期权奖励（“诱导期权”），以便他与公司签订雇佣合同。诱导期权的授予自 2026 年 1 月 5 日起生效，可用于购买 70,000 股公司普通股，行使价格等于 2025 年 12 月 31 日在纳斯达克的最后报告销售价格。诱导奖励已获得董事会独立薪酬委员会的批准，符合纳斯达克证券市场上市规则 5635(c)(4)。诱导期权的有效期为十年，并将在四年内逐步归属，第一年归属 25% 的股票期权，之后每年以三等份的方式归属，前提是 Moorhead 先生在适用的归属日期继续为公司服务。诱导奖励受公司修订和重述的 2013 年股权激励计划的条款和条件的约束。</p>
<p><strong>关于 Beyond Air</strong> <strong>®</strong> <strong>, Inc.</strong></p>
<p>Beyond Air 是一家商业阶段的医疗设备和生物制药公司，致力于利用内源性和外源性的一氧化氮（NO）的力量改善患有呼吸疾病、神经系统疾病和实体肿瘤的患者的生活。公司已获得 FDA 批准和 CE 标志，针对有缺氧呼吸衰竭的足月和近足月新生儿的首个系统 LungFit PH。Beyond Air 目前正在推进其他革命性的 LungFit 系统，进行临床试验以治疗严重的肺部感染，如病毒性社区获得性肺炎（包括 COVID-19）和非结核分枝杆菌（NTM）。</p>
<p>公司还与耶路撒冷希伯来大学合作，推进一项针对自闭症谱系障碍（ASD）和其他神经系统疾病的临床前项目。此外，Beyond Cancer, Ltd.，Beyond Air 的一个附属公司，正在研究使用专有输送系统的超高浓度 NO，以针对某些实体肿瘤进行临床前研究。有关更多信息，请访问 www.beyondair.net。</p>
<p><strong>关于 LungFit</strong> <strong>*</strong></p>
<p>Beyond Air 的 LungFit 是一种无气缸的相流发生器和输送系统，被美国食品药品监督管理局（FDA）指定为医疗设备。该设备的兼容通气机版本可以根据需要从环境空气中生成 NO，输送到肺部的浓度范围为 1 ppm 到 80 ppm。LungFit 系统有可能取代大型高压 NO 气缸，在医院环境中提供显著优势，包括大幅减少库存和存储需求，通过消除 NO2 清洗步骤提高整体安全性，并提供其他操作优势。</p>
<p>LungFit 还可以在医院环境中以 80 ppm 或更高的浓度输送 NO，以潜在治疗严重急性肺部感染（例如 COVID-19、支气管炎）和家庭环境中的慢性、难治性肺部感染（例如 NTM）。通过消除气缸，Beyond Air 计划在家庭环境中提供 NO 治疗。</p>
<p><em>*Beyond Air 的 LungFit PH 已在美国、欧盟及世界许多其他国家获得商业使用批准。Beyond Air 的其他 LungFit 系统尚未获得商业使用批准，仅供研究使用。Beyond Air 并不建议在 80 ppm 以上使用 NO 或在家中使用。</em></p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含关于吸入一氧化氮及超高浓度一氧化氮产品候选者的潜在安全性和有效性的 “前瞻性声明”，以及其在多种适应症中的治疗潜力；以及吸入一氧化氮和超高浓度一氧化氮产品候选者对患者的潜在影响和预期收益。前瞻性声明包括关于产品供应、业务、运营结果、战略或前景的期望、信念或意图的陈述。您可以通过 “似乎”、“期望”、“计划”、“预期”、“相信”、“打算”、“看”、“预测”、“目标”、“假设”、“目标” 等词语以及未来时态或条件结构（如 “将”、“可能”、“可以”、“应该” 等）来识别这些前瞻性声明，并且这些声明并不严格与历史或当前事务相关。相反，前瞻性声明涉及在声明作出时预期或预计的事件、活动、趋势或结果。由于前瞻性声明涉及尚未发生的事项，这些声明本质上受到风险和不确定性的影响，这可能导致实际结果与前瞻性声明中表达或暗示的任何未来结果存在重大差异。这些前瞻性声明仅为预测，并反映了在作出声明时对未来事件和财务表现的看法。许多因素可能导致实际活动或结果与前瞻性声明中预期的活动和结果存在重大差异，包括与筹集额外资本的能力相关的风险；未来临床前研究和临床试验的时间和结果；包括 FDA 及其他非美国监管机构在内的监管机构可能不会批准或可能延迟批准我们的产品候选者的潜在性；发现和开发新药的方法尚未得到验证，可能永远不会导致有效或可销售的产品；资助和进一步临床前研究及临床试验结果的能力；获取、维护和保护产品所使用的知识产权；获得产品的监管批准；来自使用类似技术的其他竞争者以及开发类似用途产品的其他公司的竞争；对合作伙伴的依赖；以及其他风险，这些风险可能在一定程度上在 Beyond Air 最近的 10-K 表格年度报告和其他向证券交易委员会提交的文件的 “风险因素” 部分中被识别和描述，所有这些文件均可在 Beyond Air 的网站上获取。Beyond Air 和 Beyond Cancer 没有义务更新这些前瞻性声明，也没有更新或修订这些声明的政策，除非适用法律要求。</p>
<p><strong>联系方式：</strong></p>
<p><strong>投资者关系联系人</strong> Corey Davis, Ph.D.</p>
<p>LifeSci Advisors, LLC</p>
<p>Cdavis@lifesciadvisors.com</p>
<p>(212) 915-2577</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56ZzRNaU0zTXpNNE56TTNJekl3T0RNNU1qZz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56ZzRNaU0zTXpNNE56TTNJekl3T0RNNU1qZz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MjRmOTMwODctZmRkYS00NTRhLWI4YWUtMmViNjk2YWIzZWM4LTEwOTU0OTktMjAyNS0xMi0zMC1lbg==/tiny/Beyond-Air-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MjRmOTMwODctZmRkYS00NTRhLWI4YWUtMmViNjk2YWIzZWM4LTEwOTU0OTktMjAyNS0xMi0zMC1lbg==/tiny/Beyond-Air-.png"/></p>

XAIR

<p>Beyond Air, Inc. 已任命 Dan Moorhead 为首席财务官，任职时间自 2026 年 1 月 5 日起生效。他接替了担任临时首席财务官的 Duke Dewrell。Moorhead 拥有超过 20 年的财务领导经验，曾担任 Zynex, Inc. 的首席财务官。他将负责公司的财务管理，帮助公司为 FDA 批准及其第二代 LungFit PH 设备的商业发布做好准备。Moorhead 获得了一项诱导性股票期权奖励，使他能够以设定价格购买 70,000 股普通股</p>

<p>GARDEN CITY, N.Y., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the appointment of Dan Moorhead as Chief Financial Officer, effective January 5, 2026. Duke Dewrell, the Company's Controller, who had assumed CFO responsibilities at the Company on an interim basis in November 2025, will resume his prior role as of that date.</p>
<div class="lb-trans"><p>纽约花园城，2025 年 12 月 30 日（GLOBE NEWSWIRE）-- Beyond Air, Inc.（纳斯达克：XAIR）（“Beyond Air” 或 “公司”）是一家商业阶段的医疗设备和生物制药公司，专注于利用一氧化氮（NO）的力量改善患者的生活，今天宣布任命 Dan Moorhead 为首席财务官，任职将于 2026 年 1 月 5 日生效。公司的控制人 Duke Dewrell 在 2025 年 11 月临时担任首席财务官的职责，将于该日期恢复其之前的角色。</p>
</div><p>&#34;It is a pleasure to welcome Dan to the Beyond Air team,” said Steve Lisi, Chairman and Chief Executive Officer of Beyond Air. “He brings a strong track record of guiding companies through significant growth and developing high-performing finance organizations that can support commercial scale. I look forward to leveraging his experience as we continue advancing our strategy and build a market-leading company.”</p>
<div class="lb-trans"><p>“很高兴欢迎 Dan 加入 Beyond Air 团队，” Beyond Air 的董事长兼首席执行官 Steve Lisi 表示。“他在引导公司经历显著增长和发展高效的财务组织方面拥有强大的业绩记录，这些组织能够支持商业规模。我期待利用他的经验，继续推进我们的战略，建立一家市场领先的公司。”</p>
</div><p>“I am honored to join the Beyond Air team at such a pivotal moment in the Company’s evolution. As market awareness continues to build around LungFit PH and the team prepares for the highly anticipated FDA approval of the second generation LungFit PH and subsequent commercial launch, I look forward to working closely with the leadership team to ensure strong financial stewardship and support the successful execution of our commercial strategy,” stated Mr. Moorhead.</p>
<div class="lb-trans"><p>“我很荣幸在公司发展如此关键的时刻加入 Beyond Air 团队。随着市场对 LungFit PH 的认知不断提升，团队为第二代 LungFit PH 的 FDA 批准和随后的商业发布做准备，我期待与领导团队紧密合作，以确保强有力的财务管理，并支持我们商业战略的成功执行，” Moorhead 先生表示。</p>
</div><p>Mr. Moorhead brings more than 20 years of finance leadership experience across both public and private companies. From June 2017 to August 2025, he served as Chief Financial Officer of Zynex, Inc., a publicly traded, commercial-stage medical device company, where he implemented a disciplined budgeting and forecasting framework and supported the company’s multi-year commercial expansion. Prior to Zynex, Mr. Moorhead spent 10 years at Evolving Systems, Inc. (acquired by PartnerOne, Inc.), serving as Chief Financial Officer following earlier roles as Vice President of Finance &amp; Administration and Corporate Controller. Mr. Moorhead is a CPA and holds a B.B.A. in Accounting from the University of Northern Colorado.</p>
<div class="lb-trans"><p>Moorhead 先生在公共和私人公司拥有超过 20 年的财务领导经验。从 2017 年 6 月到 2025 年 8 月，他担任 Zynex, Inc.的首席财务官，这是一家上市的商业阶段医疗设备公司，在那里他实施了严格的预算和预测框架，并支持公司的多年商业扩展。在加入 Zynex 之前，Moorhead 先生在 Evolving Systems, Inc.（被 PartnerOne, Inc.收购）工作了 10 年，担任首席财务官，之前曾担任财务与行政副总裁和公司控制人。Moorhead 先生是注册会计师，并拥有北科罗拉多大学的会计学学士学位。</p>
</div><p>In connection with his appointment, the Company granted an inducement stock option award (the &#34;Inducement Option&#34;) to Mr. Moorhead upon his entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4) (the &#34;Inducement Award&#34;). The Inducement Option is being granted effective as of January 5, 2026 and is exercisable for the purchase of 70,000 shares of the Company's common stock, at an exercise price equal to the last reported sale price on Nasdaq on December 31, 2025. The Inducement Award was approved by the independent compensation committee of the Board in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The Inducement Option has a ten-year term and will vest over a four-year period, with 25% of the shares underlying the stock option award vesting on the first anniversary of the date of grant and annually thereafter in three equal installments, subject to Mr. Moorhead's continued service with the Company through the applicable vesting dates. The Inducement Award is subject to the terms and conditions of the Company's Amended and Restated 2013 Equity Incentive Plan.</p>
<div class="lb-trans"><p>与他的任命相关，公司根据纳斯达克证券市场上市规则 5635(c)(4) 向 Moorhead 先生授予了一项诱导股票期权奖励（“诱导期权”），以便他与公司签订雇佣合同。诱导期权的授予自 2026 年 1 月 5 日起生效，可用于购买 70,000 股公司普通股，行使价格等于 2025 年 12 月 31 日在纳斯达克的最后报告销售价格。诱导奖励已获得董事会独立薪酬委员会的批准，符合纳斯达克证券市场上市规则 5635(c)(4)。诱导期权的有效期为十年，并将在四年内逐步归属，第一年归属 25% 的股票期权，之后每年以三等份的方式归属，前提是 Moorhead 先生在适用的归属日期继续为公司服务。诱导奖励受公司修订和重述的 2013 年股权激励计划的条款和条件的约束。</p>
</div><p><strong>About Beyond Air</strong> <strong>®</strong> <strong>, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Beyond Air</strong> <strong>®</strong> <strong>, Inc.</strong></p>
</div><p>Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM).</p>
<div class="lb-trans"><p>Beyond Air 是一家商业阶段的医疗设备和生物制药公司，致力于利用内源性和外源性的一氧化氮（NO）的力量改善患有呼吸疾病、神经系统疾病和实体肿瘤的患者的生活。公司已获得 FDA 批准和 CE 标志，针对有缺氧呼吸衰竭的足月和近足月新生儿的首个系统 LungFit PH。Beyond Air 目前正在推进其他革命性的 LungFit 系统，进行临床试验以治疗严重的肺部感染，如病毒性社区获得性肺炎（包括 COVID-19）和非结核分枝杆菌（NTM）。</p>
</div><p>The Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.</p>
<div class="lb-trans"><p>公司还与耶路撒冷希伯来大学合作，推进一项针对自闭症谱系障碍（ASD）和其他神经系统疾病的临床前项目。此外，Beyond Cancer, Ltd.，Beyond Air 的一个附属公司，正在研究使用专有输送系统的超高浓度 NO，以针对某些实体肿瘤进行临床前研究。有关更多信息，请访问 www.beyondair.net。</p>
</div><p><strong>About LungFit</strong> <strong>*</strong></p>
<div class="lb-trans"><p><strong>关于 LungFit</strong> <strong>*</strong></p>
</div><p>Beyond Air's LungFit is a cylinder-free, phasic flow generator and delivery system designated as a medical device by the U.S. Food and Drug Administration (FDA). The ventilator-compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders, providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety by eliminating NO2 purging steps, and offering other operational benefits.</p>
<div class="lb-trans"><p>Beyond Air 的 LungFit 是一种无气缸的相流发生器和输送系统，被美国食品药品监督管理局（FDA）指定为医疗设备。该设备的兼容通气机版本可以根据需要从环境空气中生成 NO，输送到肺部的浓度范围为 1 ppm 到 80 ppm。LungFit 系统有可能取代大型高压 NO 气缸，在医院环境中提供显著优势，包括大幅减少库存和存储需求，通过消除 NO2 清洗步骤提高整体安全性，并提供其他操作优势。</p>
</div><p>LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g., COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g., NTM). With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting.</p>
<div class="lb-trans"><p>LungFit 还可以在医院环境中以 80 ppm 或更高的浓度输送 NO，以潜在治疗严重急性肺部感染（例如 COVID-19、支气管炎）和家庭环境中的慢性、难治性肺部感染（例如 NTM）。通过消除气缸，Beyond Air 计划在家庭环境中提供 NO 治疗。</p>
</div><p><em>*Beyond Air's LungFit PH is approved for commercial use in the United States, European Union, and many other countries around the world. Beyond Air's other LungFit systems are not approved for commercial use and are for investigational use only. Beyond Air is not suggesting NO use over 80 ppm or use at home.</em></p>
<div class="lb-trans"><p><em>*Beyond Air 的 LungFit PH 已在美国、欧盟及世界许多其他国家获得商业使用批准。Beyond Air 的其他 LungFit 系统尚未获得商业使用批准，仅供研究使用。Beyond Air 并不建议在 80 ppm 以上使用 NO 或在家中使用。</em></p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p><em>This press release contains “forward-looking statements” concerning the potential safety and efficacy of inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings, business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “appears,” “expects,” “plans,” “anticipates,” “believes” “expects,” “intends,” “looks,” “projects,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air’s most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air’s website. Beyond Air and Beyond Cancer undertake no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law.</em></p>
<div class="lb-trans"><p>本新闻稿包含关于吸入一氧化氮及超高浓度一氧化氮产品候选者的潜在安全性和有效性的 “前瞻性声明”，以及其在多种适应症中的治疗潜力；以及吸入一氧化氮和超高浓度一氧化氮产品候选者对患者的潜在影响和预期收益。前瞻性声明包括关于产品供应、业务、运营结果、战略或前景的期望、信念或意图的陈述。您可以通过 “似乎”、“期望”、“计划”、“预期”、“相信”、“打算”、“看”、“预测”、“目标”、“假设”、“目标” 等词语以及未来时态或条件结构（如 “将”、“可能”、“可以”、“应该” 等）来识别这些前瞻性声明，并且这些声明并不严格与历史或当前事务相关。相反，前瞻性声明涉及在声明作出时预期或预计的事件、活动、趋势或结果。由于前瞻性声明涉及尚未发生的事项，这些声明本质上受到风险和不确定性的影响，这可能导致实际结果与前瞻性声明中表达或暗示的任何未来结果存在重大差异。这些前瞻性声明仅为预测，并反映了在作出声明时对未来事件和财务表现的看法。许多因素可能导致实际活动或结果与前瞻性声明中预期的活动和结果存在重大差异，包括与筹集额外资本的能力相关的风险；未来临床前研究和临床试验的时间和结果；包括 FDA 及其他非美国监管机构在内的监管机构可能不会批准或可能延迟批准我们的产品候选者的潜在性；发现和开发新药的方法尚未得到验证，可能永远不会导致有效或可销售的产品；资助和进一步临床前研究及临床试验结果的能力；获取、维护和保护产品所使用的知识产权；获得产品的监管批准；来自使用类似技术的其他竞争者以及开发类似用途产品的其他公司的竞争；对合作伙伴的依赖；以及其他风险，这些风险可能在一定程度上在 Beyond Air 最近的 10-K 表格年度报告和其他向证券交易委员会提交的文件的 “风险因素” 部分中被识别和描述，所有这些文件均可在 Beyond Air 的网站上获取。Beyond Air 和 Beyond Cancer 没有义务更新这些前瞻性声明，也没有更新或修订这些声明的政策，除非适用法律要求。</p>
</div><p><strong>CONTACTS:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p><strong>Investor Relations contacts</strong> Corey Davis, Ph.D.</p>
<div class="lb-trans"><p><strong>投资者关系联系人</strong> Corey Davis, Ph.D.</p>
</div><p>LifeSci Advisors, LLC</p>
<div class="lb-trans"><p>LifeSci Advisors, LLC</p>
</div><p>Cdavis@lifesciadvisors.com</p>
<div class="lb-trans"><p>Cdavis@lifesciadvisors.com</p>
</div><p>(212) 915-2577</p>
<div class="lb-trans"><p>(212) 915-2577</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56ZzRNaU0zTXpNNE56TTNJekl3T0RNNU1qZz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxNzg4MiM3MzM4NzM3IzIwODM5Mjg="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MjRmOTMwODctZmRkYS00NTRhLWI4YWUtMmViNjk2YWIzZWM4LTEwOTU0OTktMjAyNS0xMi0zMC1lbg==/tiny/Beyond-Air-.png" alt="" original-src="https://ml.globenewswire.com/media/MjRmOTMwODctZmRkYS00NTRhLWI4YWUtMmViNjk2YWIzZWM4LTEwOTU0OTktMjAyNS0xMi0zMC1lbg==/tiny/Beyond-Air-.png"/></p>

Beyond Air®任命 Dan Moorhead 为首席财务官 | XAIR 股票资讯